Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Swiebocka, G. Siergiejko, P. Rapiejko, Z. Siergiejko (Bialystok, Warsaw, Poland). Maintenance schedule of subcutaneous allergoid immunotherapy more efficacious than pre-seasonal. Eur Respir J 2011; 38: Suppl. 55, 264

Member's Comments

No comment yet.

Related content which might interest you: Compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy Source: Annual Congress 2012 - Aspects of clinical asthma Year: 2012 Specific immunotherapy in grass-pollen allergic asthma combinated with inhaled steroid therapy vs specific immunotherapy allone Source: Eur Respir J 2001; 18: Suppl. 33, 431s Year: 2001 Evaluation and efficacy of allergen immunotherapy in asthma Source: Eur Respir J 2005; 26: Suppl. 49, 399s Year: 2005 Efficacy and safety of high-dose inhaled corticosteroids therapy in children with asthma Source: Annual Congress 2010 - Allergy and risk factors in paediatrics Year: 2010 Efficacy and safety of 300IR 5-grass pollen sublingual tablet in allergic patients with and without asthma Source: Annual Congress 2012 - Clinical aspects and treatment of asthma and allergic respiratory diseases Year: 2012 Sublingual allergen specific immunotherapy in children with respiratory allergies – long lasting efficacy Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Adherence to sublingual immunotherapy in patients allergic to mites Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E Year: 2011 Hydrofluoroalkane beclomethasone dipropionate extra fine aerosol efficacy response at reduced dose compared to other inhaled corticosteroid treatment regimens Source: Eur Respir J 2001; 18: Suppl. 33, 70s Year: 2001 Decreasing dose protocol for omalizumab treatment in oral corticosteroid allergic asthma patients Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E Year: 2011 Comparison of two twice-daily doses of budesonide/formoterol maintenance and reliever therapy Source: Eur Respir J 2010; 36: 524-530 Year: 2010 Switching asthma patients using high-dose inhaled steroids to budesonide/formoterol maintenance and reliever therapy Source: Annual Congress 2010 - Management of airway disease Year: 2010 Effects of oromucosal immunotherapy (SLIT) in children with respiratory allergy Source: Eur Respir J 2002; 20: Suppl. 38, 525s Year: 2002 Low-dose single-inhaler budesonide/formoterol administered once daily is effective in mild-persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 158s Year: 2001 Safety of budesonide/formoterol maintenance and reliever therapy in asthma trials Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008 Optimum dosing regimen for repeated low dose allergen challenge in chronic allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 103s Year: 2001 Long-term treatment with fluticasone propionate/formoterol fumarate (FLUT/FORM) combination therapy is well-tolerated and provides sustained effectiveness in paediatric patients with asthma Source: Annual Congress 2011 - Treating childhood asthma Year: 2011 Scientific rationale for using a single inhaler for asthma control by comparison of the effectiveness and safety of formoterol/budesonide turbuhaler as physician-guided adjustable maintenance dosing regimen versus formoterol/budesonide given as fixed dose of twice daily therapy in the management of bronchial asthma Source: Annual Congress 2009 - Aspects of clinical asthma Year: 2009 Oral steroid-sparing effect of high-dose inhaled corticosteroids in asthma Source: Eur Respir J, 55 (1) 1901147; 10.1183/13993003.01147-2019 Year: 2020 Response of children with bronchial asthma to combined therapy with an oral immunostimulating drug and antileukotrienes Source: Eur Respir J 2005; 26: Suppl. 49, 159s Year: 2005 Durability of mepolizumab treatment response between doses Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019